share_log

三叶草生物-B(02197.HK)公布其二价RSV候选疫苗SCB-1019与GSK RSV疫苗AREXVY头对头比较获得积极临床数据

Adidas Biologics-B (02197.HK) announced positive clinical data from the head-to-head comparison of its bivalent RSV candidate vaccine SCB-1019 with the GSK RSV vaccine AREXVY.

Gelonghui Finance ·  Oct 29, 2024 06:20

Grain Live 29th October | Clover Biopharmaceuticals-B (02197.HK) announced that in Phase I clinical trial, the divalent RSV PreF trimer subunit candidate vaccine SCB-1019 (developed based on Clover Biopharmaceuticals' unique Trimer-Tag protein trimerization vaccine technology platform) evaluated without the use of adjuvants, obtained more positive immunogenicity and safety data in elderly subjects compared to GSK's RSV vaccine AREXVY using AS01E adjuvant in a head-to-head comparison.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment